How Much Does Isavuconazonium Cost?
The cost of isavuconazonium, sold under the brand name Cresemba, varies depending on factors such as insurance coverage, pharmacy, and dosage. The price for a 30-day supply of Cresemba capsules can range from approximately $8,000 to over $10,000 without insurance [1]. For intravenous administration, the cost can be even higher.
What Financial Assistance Programs Are Available for Cresemba?
Patients who are prescribed Cresemba may be eligible for financial assistance programs. The Cresemba Savings Card program offers eligible commercially insured patients savings of up to $100 per prescription [2]. For patients facing financial hardship who are uninsured or underinsured, the Cresemba Patient Assistance Program may provide medication at no cost [2]. Information about these programs is typically available through the manufacturer's website or by speaking with a healthcare provider.
How Does Cresemba Compare to Other Antifungal Medications in Terms of Cost?
Compared to other antifungal medications used to treat serious fungal infections, Cresemba can be more expensive. For example, voriconazole (Vfend) or posaconazole (Noxafil) may have lower list prices, but treatment costs also depend on factors like the duration of therapy, dosing, and the specific formulation used. The newer triazole antifungals like isavuconazonium often represent a significant investment in treatment.
What Is the Role of Insurance in the Cost of Isavuconazonium?
Insurance coverage significantly impacts the out-of-pocket cost of isavuconazonium. Many insurance plans cover Cresemba, but patients may still be responsible for co-pays, deductibles, or co-insurance, which can lead to substantial expenses. The formulary status of Cresemba within a specific insurance plan dictates the level of coverage and potential cost-sharing. Patients are advised to check with their insurance provider for detailed information on their coverage.
What Does the Future Hold for Isavuconazonium Pricing?
Future pricing of isavuconazonium will likely be influenced by market competition, patent expirations, and the development of biosimilar versions. While no biosimilars are currently available for isavuconazonium, the eventual introduction of such alternatives could lead to price reductions. The ongoing clinical use and evidence of effectiveness for Cresemba may also play a role in its long-term market positioning and associated costs.
What Are the Dosing and Administration Options for Isavuconazonium?
Isavuconazonium is available in two forms: an oral capsule and an intravenous (IV) solution [1]. The typical dosage regimen involves an initial loading dose followed by a daily maintenance dose. The specific dose and duration of treatment depend on the type of fungal infection being treated and the patient's individual characteristics. Both oral and IV formulations are used to treat invasive aspergillosis and invasive mucormycosis [1].
---
Sources:
[1] https://www.drugs.com/price-guide/cresemba
[2] https://www.cresemba.com/patient-support